6 Citations (Scopus)

Abstract

TAFRO syndrome is a newly recognized variant of idiopathic multicentric Castleman disease (iMCD) that involves a constellation of syndromes: thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R), and organomegaly (O). Thrombocytopenia and severe anasarca accompanied by relatively low serum immunoglobulin levels are characteristic clinical findings of TAFRO syndrome that are not present in iMCD-not otherwise specified (iMCD-NOS). Lymph node biopsy is recommended to exclude other diseases and to diagnose TAFRO syndrome, which reveals characteristic histopathological findings similar to hyaline vascular-type CD. TAFRO syndrome follows a more aggressive course, compared with iMCD-NOS, and there is no standard treatment.

Original languageEnglish
Pages (from-to)107-118
Number of pages12
JournalHematology/Oncology Clinics of North America
Volume32
Issue number1
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Thrombocytopenia
Edema
Reticulin
Hyalin
Blood Vessels
Immunoglobulins
Fibrosis
Fever
Lymph Nodes
Biopsy
Serum
Multi-centric Castleman's Disease
Therapeutics

Keywords

  • Castleman disease
  • Clinical features
  • Pathogenesis
  • TAFRO syndrome

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

TAFRO Syndrome. / Igawa, Takuro; Sato, Yasuharu.

In: Hematology/Oncology Clinics of North America, Vol. 32, No. 1, 01.02.2018, p. 107-118.

Research output: Contribution to journalReview article

@article{9e71d6ac25a748f79f992bc4db81cf66,
title = "TAFRO Syndrome",
abstract = "TAFRO syndrome is a newly recognized variant of idiopathic multicentric Castleman disease (iMCD) that involves a constellation of syndromes: thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R), and organomegaly (O). Thrombocytopenia and severe anasarca accompanied by relatively low serum immunoglobulin levels are characteristic clinical findings of TAFRO syndrome that are not present in iMCD-not otherwise specified (iMCD-NOS). Lymph node biopsy is recommended to exclude other diseases and to diagnose TAFRO syndrome, which reveals characteristic histopathological findings similar to hyaline vascular-type CD. TAFRO syndrome follows a more aggressive course, compared with iMCD-NOS, and there is no standard treatment.",
keywords = "Castleman disease, Clinical features, Pathogenesis, TAFRO syndrome",
author = "Takuro Igawa and Yasuharu Sato",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.hoc.2017.09.009",
language = "English",
volume = "32",
pages = "107--118",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - TAFRO Syndrome

AU - Igawa, Takuro

AU - Sato, Yasuharu

PY - 2018/2/1

Y1 - 2018/2/1

N2 - TAFRO syndrome is a newly recognized variant of idiopathic multicentric Castleman disease (iMCD) that involves a constellation of syndromes: thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R), and organomegaly (O). Thrombocytopenia and severe anasarca accompanied by relatively low serum immunoglobulin levels are characteristic clinical findings of TAFRO syndrome that are not present in iMCD-not otherwise specified (iMCD-NOS). Lymph node biopsy is recommended to exclude other diseases and to diagnose TAFRO syndrome, which reveals characteristic histopathological findings similar to hyaline vascular-type CD. TAFRO syndrome follows a more aggressive course, compared with iMCD-NOS, and there is no standard treatment.

AB - TAFRO syndrome is a newly recognized variant of idiopathic multicentric Castleman disease (iMCD) that involves a constellation of syndromes: thrombocytopenia (T), anasarca (A), fever (F), reticulin fibrosis (R), and organomegaly (O). Thrombocytopenia and severe anasarca accompanied by relatively low serum immunoglobulin levels are characteristic clinical findings of TAFRO syndrome that are not present in iMCD-not otherwise specified (iMCD-NOS). Lymph node biopsy is recommended to exclude other diseases and to diagnose TAFRO syndrome, which reveals characteristic histopathological findings similar to hyaline vascular-type CD. TAFRO syndrome follows a more aggressive course, compared with iMCD-NOS, and there is no standard treatment.

KW - Castleman disease

KW - Clinical features

KW - Pathogenesis

KW - TAFRO syndrome

UR - http://www.scopus.com/inward/record.url?scp=85035013551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035013551&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2017.09.009

DO - 10.1016/j.hoc.2017.09.009

M3 - Review article

C2 - 29157612

AN - SCOPUS:85035013551

VL - 32

SP - 107

EP - 118

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 1

ER -